287 related articles for article (PubMed ID: 19490647)
1. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
Gregory TK; Wald D; Chen Y; Vermaat JM; Xiong Y; Tse W
J Hematol Oncol; 2009 Jun; 2():23. PubMed ID: 19490647
[TBL] [Abstract][Full Text] [Related]
2. Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics.
Wald D; Vermaat JM; Peleg G; Tse W
Curr Hematol Malig Rep; 2008 Apr; 3(2):83-8. PubMed ID: 20425451
[TBL] [Abstract][Full Text] [Related]
3. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
4. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal Abnormalities and Prognosis in
Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas PY; Dombret H; Preudhomme C; Micol JB; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch JH; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
J Clin Oncol; 2019 Oct; 37(29):2632-2642. PubMed ID: 31430225
[TBL] [Abstract][Full Text] [Related]
6. Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.
Vasudevan Nampoothiri R; Tang K; Schuh A; Lam W; Maze D; Michelis FV; Chan S; Gupta V; Kim D; Kumar R; Lipton JH; Mattsson J; Minden M; Schimmer A; Sibai H; Viswabandya A; Yee K; Murphy T; Law AD
Eur J Haematol; 2023 Jun; 110(6):618-625. PubMed ID: 36732677
[TBL] [Abstract][Full Text] [Related]
7. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.
Lin TL; Smith BD
Am J Med Sci; 2011 May; 341(5):404-8. PubMed ID: 21522052
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
9. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Falini B; Martelli MP
Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
[TBL] [Abstract][Full Text] [Related]
10. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
Staffas A; Kanduri M; Hovland R; Rosenquist R; Ommen HB; Abrahamsson J; Forestier E; Jahnukainen K; Jónsson ÓG; Zeller B; Palle J; Lönnerholm G; Hasle H; Palmqvist L; Ehrencrona H;
Blood; 2011 Nov; 118(22):5905-13. PubMed ID: 21967978
[TBL] [Abstract][Full Text] [Related]
11. Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics.
Strunk CJ; Platzbecker U; Thiede C; Schaich M; Illmer T; Kang Z; Leahy P; Li C; Xie X; Laughlin MJ; Lazarus HM; Gerson SL; Bunting KD; Ehninger G; Tse W
Am J Hematol; 2009 May; 84(5):308-9. PubMed ID: 19396856
[TBL] [Abstract][Full Text] [Related]
12. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
13. [Identification of molecular markers in children with acute myeloid leukemia (AML)].
Ilenčíková D; Sýkora J; Mikulášová Z; Repiská V
Klin Onkol; 2012; 25(1):26-35. PubMed ID: 22348217
[TBL] [Abstract][Full Text] [Related]
14. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
[TBL] [Abstract][Full Text] [Related]
15. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
Marcucci G; Mrózek K; Bloomfield CD
Curr Opin Hematol; 2005 Jan; 12(1):68-75. PubMed ID: 15604894
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia.
Zhang Q; Bai S; Vance GH
Methods Mol Biol; 2013; 999():105-21. PubMed ID: 23666693
[TBL] [Abstract][Full Text] [Related]
17. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.
Heidrich K; Thiede C; Schäfer-Eckart K; Schmitz N; Aulitzky WE; Krämer A; Rösler W; Hänel M; Einsele H; Baldus CD; Trappe RU; Stölzel F; Middeke JM; Röllig C; Taube F; Kramer M; Serve H; Berdel WE; Ehninger G; Bornhäuser M; Schetelig J;
Ann Oncol; 2017 Nov; 28(11):2793-2798. PubMed ID: 28945881
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
